Results 51 to 60 of about 10,259 (201)
THB activates cAMP‐Epac1 signaling to suppress autophagy‐dependent ferroptosis and alleviate DOX‐induced liver injury. ABSTRACT This study investigated the hepatoprotective mechanism of tetrahydroberberine (THB) against doxorubicin (DOX)‐induced liver injury.
Cheng Teng +9 more
wiley +1 more source
Harnessing the Folding of Antitumor Peptides for Controlled Carrier‐Free Drug Delivery
A disulfide‐bridged stapled p53 α‐helix co‐assembled with doxorubicin into protease‐resistant nanocomplexes. Reductive intracellular conditions induced helix refolding and nanostructure disassembly, which enabled the coordinated release of the chemotherapeutic agent and anticancer peptide.
Jae Yun Lee +9 more
wiley +1 more source
HER2‐targeted AIE780‐A1811 nanoparticles self‐assemble via amide coupling of a mitochondria‐directed photosensitizer with the ADC SHR‐A1811. Upon 660 nm irradiation, they generate ROS, photothermal effects, and controlled drug release, inducing immunogenic pyroptosis and M2‐to‐M1 macrophage reprogramming. This dual action remodels the immunosuppressive
Xiaohong Liu +12 more
wiley +1 more source
Abstract Ninety percent of all primary liver malignancies are hepatocellular carcinomas (HCC), making liver cancer the third most common cause of cancer‐associated mortality. Different patterns of programmed cell death (PCD) are crucial for the survival of tumors, and they might serve as a prognostic marker for HCC.
Lin Ding +10 more
wiley +1 more source
Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally +6 more
wiley +1 more source
Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder +7 more
wiley +1 more source
The Cleavage of DNA by Type-I DNA Topoisomerases
K, Kirkegaard, G, Pflugfelder, J C, Wang
openaire +2 more sources
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys +14 more
wiley +1 more source
Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra +5 more
wiley +1 more source
Chromosomal DNA double‐strand breaks (DSBs) are repaired by homologous recombination and nonhomologous end joining (NHEJ). Recent work has additionally established theta‐mediated end‐joining (TMEJ) as a mechanism for DSB joining. Cells lacking NHEJ and TMEJ can repair DSBs in a homology‐dependent manner.
Shinta Saito +6 more
wiley +1 more source

